Volume 13.19 | May 21

Issue 13.19, May 21, 2012
Cell Therapy News - Your Industry in an Instant
Your Industry in an InstantTwitter Facebook
Publications | Reviews | Science | Policy | Business | NIH | CBER | Regulatory | Events | Jobs

TOP STORY
Scientist Grows Bone from Human Embryonic Stem Cells
The study is the first example of using bone cell progenitors derived from human embryonic stem cells to grow compact bone tissue in quantities large enough to repair centimeter-sized defects. [Press release from The New York Stem Cell Foundation discussing online prepublication in the Proceedings of the National Academy of Sciences, USA] Press Release | Abstract

Got Paper? Use StemLab™. Visit us at ISCT, booth #210 or schedule a demo


PUBLICATIONS (Ranked by Impact Factor of the Journal)

Erosion of Dosage Compensation Impacts Human iPSC Disease Modeling
Scientists showed that although low-passage female human induced pluripotent stem cells (hiPSCs) retain the inactive X chromosome of the somatic cell they are derived from, over time in culture they undergo an erosion of X chromosome inactivation. [Cell Stem Cell] Abstract

Hepatocyte Growth Factor Mediates Mesenchymal Stem Cell-Induced Recovery in Multiple Sclerosis Models
Investigators demonstrated that conditioned medium from human mesenchymal stem cells reduces functional deficits in mouse MOG35-55-induced experimental autoimmune encephalomyelitis and promotes the development of oligodendrocytes and neurons. [Nat Neurosci] Abstract | Press Release

Early-Outgrowth Bone Marrow Cells Attenuate Renal Injury and Dysfunction via an Antioxidant Effect in a Mouse Model of Type 2 Diabetes
Researchers found that early-outgrowth cells derived from both diabetic db/db and nondiabetic db/m mice were equally effective in ameliorating kidney injury and oxidative stress. [Diabetes] Abstract

Telomerase Gene Therapy in Adult and Old Mice Delays Aging and Increases Longevity without Increasing Cancer
Treatment of one- and two-year old mice with an adeno associated virus of wide tropism expressing mouse TERT had remarkable beneficial effects on health and fitness, including insulin sensitivity, osteoporosis, neuromuscular coordination and several molecular biomarkers of aging. Telomerase-treated mice, both at one-year and at two-year of age, had an increase in median lifespan of 24% and 13%, respectively. [EMBO Mol Med] Abstract | Press Release

Return of the Metabolic Trajectory to the Original Area after Human Bone Marrow Mesenchymal Stem Cell Transplantation for the Treatment of Fulminant Hepatic Failure
To clarify the metabolic mechanism of human bone marrow mesenchymal stem cell (hBMSC) transplantation in fulminant hepatic failure (FHF), plasma collected from FHF pigs that received transplantation of hBMSCs was examined using metabolic analysis to identify the key molecular markers that regulate recovery. [J Proteome Res] Abstract

Successful Reprogramming of Differentiated Cells by Somatic Cell Nuclear Transfer, Using In Vitro-Matured Oocytes with a Modified Activation Method
Successful reprogramming of human somatic cells was achieved using in vitro-matured oocytes by somatic cell nuclear transfer and improved with a modified activation method. [J Tissue Eng Regen Med] Abstract

Long-Term Results of Spinal Cord Injury Therapy Using Mesenchymal Stem Cells Derived from Bone Marrow in Humans
Three of the ten patients with spinal cord injury who were directly injected with autologous mesenchymal stem cells showed improvement in the motor power of the upper extremities and in activities of daily living, as well as significant magnetic resonance imaging and electrophysiological changes during long-term follow-up. [Neurosurgery] Abstract

Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency
Researchers performed adeno-associated viral vector-mediated gene transfer of the human aromatic L-amino acid decarboxylase (AADC) gene bilaterally into the putamen of four patients four to six years of age. [Sci Transl Med] Abstract | Press Release

Multipotent Stromal Stem Cells from Human Placenta Demonstrate High Therapeutic Potential
Investigators described human chorionic mesenchymal stem cell lines obtained from the chorion of human term placenta with high therapeutic potential in human organ pathology. [Stem Cells Transl Med]
Abstract | Press Release

Bioengineered Myocardium Derived from Induced Pluripotent Stem Cells Improves Cardiac Function and Attenuates Cardiac Remodeling following Chronic Myocardial Infarction in Rats
The authors developed cardiac tissue sheets, termed bioengineered myocardium (BM), from mouse induced pluripotent stem cells and measured cardiac performance following BM implantation in a rat chronic myocardial infarction model. [Stem Cells Transl Med] Abstract

Friends love mTeSR1, too. You and a friend can both receive a FREE bottle of mTeSR1. (Terms and conditions apply). Learn More.



SCIENCE NEWS

Cardium Reports New Catheter-Based Methods Significantly Boost Cardiac Gene Delivery
Researchers have developed and tested a new method to induce transient ischemia during a non-surgical interventional cardiac procedure, which when coupled with the infusion of nitroglycerin, boosts the delivery of an adenovector gene construct into heart cells. [Press release from Cardium Therapeutics discussing research presented at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting, Philadelphia]
Press Release

Atu027, a First in Class RNAi Therapy, Demonstrates Potential Antitumor Activity in Cancer Patients and Possible Biomarker Identified
Silence Therapeutics plc announced that top line data from its ongoing Phase I trial of Atu027 show that of the 33 patients treated in the first ten cohorts of the study, ten patients experienced stable disease after three months. [Press release from Silence Therapeutics plc discussing research to be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release

Cardiac Function in Pre-Clinical Diabetic Diastolic Heart Failure Subjects Improved by Pluristem’s PLX Cells
Pluristem Therapeutics, Inc. announced that cardiac function in a diabetic-induced diastolic dysfunction in animals improved following PLacental eXpanded (PLX cells) administration. [Pluristem Therapeutics, Inc.]
Press Release

Cytomedix Announces Expansion of Phase II Study to Treat Post-Acute Ischemic Stroke at Up to 15 U.S. Clinical Sites
Cytomedix, Inc. announced that the independent Data Safety Monitoring Board reviewing the safety data from the ongoing RECOVER-Stroke trial has recommended that the Phase II trial of ALD-401, a unique and differentiated stem cell population derived from patients’ own bone marrow, can continue as designed. [Cytomedix, Inc.] Press Release

See Our Case Study: Determine Which Species Is Best For Testing Your Class Of Compound


 
POLICY

New Global Research Council Takes Off
A new group of government research funders from around the world announced that it will try to find common ground on two big issues in its inaugural year: defining research integrity and promoting open access to scientific information. [Global Research Council] Press Release

South Korean Research Center Seeks Place at the Top
South Korea has launched an ambitious institute that it hopes will eventually rank alongside Germany’s Max Planck Society and Japan’s RIKEN as one of the world’s leading basic-research institutions. [South Korean President, South Korea] Press Release

Chinese University Wins Degree of Freedom
South University of Science and Technology of China to pioneer educational reform without government control. [Ministry of Education, China] Press Release



BUSINESS

ReNeuron Signs Cell Manufacturing Contract for Completion of Stroke Clinical Trial; Recruitment of Patients for Remaining Two Dose Cohorts on Track
ReNeuron announced that it signed a new cell manufacturing contract with Angel Biotechnology Holdings plc to perform GMP drug product manufacturing services to serve the remaining part of the PISCES Phase I clinical trial of ReNeuron’s ReN001 stem cell therapy for stroke. [ReNeuron Group plc] Press Release

Fibrocell Science, Inc. Announces Exclusive License Agreement with UCLA on Dermal Cell Research to Advance the Development of Personalized Cell Therapies
Fibrocell Science, Inc. announced that it has signed an exclusive license agreement with The Regents of the University of California, under which it acquired the rights to commercially apply discoveries resulting from the scientific collaboration between the University of California, Los Angeles (UCLA) and Fibrocell Science, Inc. [Fibrocell Science, Inc.] Press Release

Fibrocell Science, Inc. and Top University Investigators Form Scientific Initiative to Assist in Securing Grant Funding for Research to Advance the Development of Personalized Cell Therapies
Fibrocell Science, Inc. announced the formation of the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives Initiative in collaboration with researchers from a number of different universities across the U.S. [Fibrocell Science, Inc.] Press Release

Groundbreaking Alzheimer’s Disease Prevention Trial Announced
In collaboration with the National Institutes of Health, Banner Alzheimer’s Institute, University of Antioquia in Colombia and Genentech announced the first-ever prevention trial in cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. [Banner Alzheimer’s Institute]
Press Release

Research Investment in Bone Marrow Failure Disease
Two research projects focused on a bone marrow failure disease recently received funding from the Aplastic Anemia and Myelodysplasia Association of Canada and the Canadian Institutes of Health Research. [Canadian Institutes of Health Research] Press Release

Gamida Cell Closes $10 Million E Financing Round Earmarked to Support the Global Commercialization of the Company’s Lead Product StemEx® for Leukemia and Lymphoma
The financing will be used to support the global commercialization of the company’s lead cell therapy product, StemEx, in development as an alternative therapeutic treatment for patients with blood cancers who can be cured by bone marrow transplantation but do not have a matched bone marrow donor. [Gamida Cell]
Press Release

Kyoto University Granted Its Third iPSC Patent in the U.S.
Kyoto University was granted its third patent associated with the method to generate induced pluripotent stem cells (iPSCs) by the United States Patent and Trademark Office, following its first and second ones granted last year. [Center for iPS Cell Research and Application, Kyoto University] Press Release

World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Osiris Therapeutics Inc. announced it has received market authorization from Health Canada to market its stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. [Osiris Therapeutics Inc.] Press Release

Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology Platforms Targeting Pathogenic Protein Aggregates Focused on Huntington’s and Parkinson’s Diseases
Intellect Neurosciences, Inc. announced it has filed three new patent applications with the United States Patent and Trademark Office, which expand the Company’s immunotherapy pipeline. [Intellect Neurosciences, Inc.] Press Release

Northwest Bio Provides Update on DCVax®-L Brain Cancer Trial
Northwest Biotherapeutics announced that it now has 41 clinical trial sites open and recruiting across the United States in its ongoing clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme. [Northwest Biotherapeutics, Inc.] Press Release

Juventas Therapeutics Enrolling Patients in Phase IIa STOP-CLI Clinical Trial
Juventas Therapeutics reported that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia (CLI). [PR Newswire] Press Release



NIH

Obama Administration Presents National Plan to Fight Alzheimer’s Disease
The National Plan to Address Alzheimer’s Disease sets forth five goals, including the development of effective prevention and treatment approaches for Alzheimer’s disease and related dementias by 2025. Press Release

Notice of NIH Piloting of Procedures for Special Council Review of Research Applications from PD(s)/PI(s) with More than $1.5 Million Total Annual NIH Support (NOT-OD-12-110)

Notice of Correction to Application Due Date, Expiration Date, Funds Available and Award Budget for RFA-FD-12-021 Pharmacokinetics Studies of Tacrolimus in Transplant Patients (U01) (NOT-FD-12-010)

The NIH Centers for Accelerated Innovations (U54) (RFA-HL-13-008)

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2012-12001)

Center for Scientific Review; Notice of Closed Meetings (FR Doc No: 2012-11852)

Center For Scientific Review; Notice of Closed Meetings (FR Doc No: 2012-11764)

Government-Owned Inventions; Availability for Licensing (FR Doc No: 2012-11691)

National Cancer Institute; Notice of Closed Meetings (FR Doc No: 2012-11746)



CBER
June 12, 2012: Blood Products Advisory Committee Meeting Announcement


REGULATORY

Food and Drug Administration (United States)

Blood Products Advisory Committee; Notice of Meeting (FR Doc No: 2012-12164)



EVENTS

NEW The Jackson Laboratory: JAX Colony Management System (JCMS) Database Live Tutorial
May 31, 1:00PM (ET in US)
Webinar

NEW IBC’s 8th Annual Cell Line Development & Engineering
June 6-8, 2012
San Francisco, United States

Visit our events page to see a complete list of events in the cell, gene and immunotherapy community.



JOB OPPORTUNITIES

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

iPSC Scientist Position – Laboratory of Translational Cell Biology (The Bassell Lab, Emory University)

Postdoctoral Position – Translational Breast Cancer Research (ISREC/EPFL)

Senior Scientist (Techshot, Inc.)

Business Development Manager – Stem Cell (SynGen Inc.)

Controller (SynGen Inc.)

Director: Regulatory Affairs (SynGen Inc.)

Manufacturing Manager (SynGen Inc.)

Chief Scientific Officer (SynGen Inc.)

Postdoctoral Fellow – Department of Bioengineering and Barbara Davis Center (University of Colorado at Denver)

Postdoctoral Position – GIGA-Neurosciences (University of Liège)

Postdoctoral Position – Spinal Cord Neural Stem Cells (Institute for Neurosciences of Montpellier)

Cellular Therapy Lab Specialist (The University of Texas Medical School at Houston)


Recruit Top Talent:
Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.